HOME >> BIOLOGY >> NEWS
Nucleic acid-amplification testing further safeguards nation's blood supply

State-of-the-art testing systems to screen donated blood have improved the safety of the nation's blood supply by preventing the transmission of potentially deadly viruses, according to a new study funded by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health. Nucleic acid-amplification testing (NAT) has helped prevent the transmission of approximately five HIV-1 infections and 56 hepatitis C virus (HCV) infections each year since it began being used in the United States as an investigational screening test in mid-1999. The study is published in the August 19 issue of the New England Journal of Medicine.

"Risks to blood recipients from transfusion-transmitted viruses such as HIV and hepatitis are already extremely low, in part because of increased surveillance and improved testing," said Barbara Alving, M.D., NHLBI acting director. "NAT enhances the safety of the nation?s blood supply by further reducing these risks."

The study is the first and only one of its scope to show the effectiveness of the NAT assay system nationally. All major blood donation laboratories in the United States participated, accounting for more than 98 percent of tested blood donations. Many organizations collaborated on the research, including the American Red Cross, Blood Systems Research Institute, America's Blood Centers, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention.

The study investigators analyzed all donations that detected ribonucleic acid (RNA) from HIV-1 and HCV by NAT between 1999 and 2002. The researchers then looked to see which of these infected donations had been missed by tests to detect viral antibodies or antigens (proteins from the virus), the types of screening previously used. They concluded that NAT reduced the risk of HIV-1 and HCV infections associated with blood transfusion to approximately 1 in 2 million blood units. In comparison,
'"/>

Contact: NHLBI Communications Office
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung, and Blood Institute
18-Aug-2004


Page: 1 2 3

Related biology news :

1. Far more men than women favor routine paternity testing at birth
2. Clinical judgement still counts strongly alongside genetic testing
3. Genetic testing of embryos to pick savior sibling OK with most Americans
4. Annual bioethics forum to explore genetic testing
5. New toxicity test could cut animal testing
6. Revised guidelines published for testing for hereditary type of colorectal cancer
7. Study calls for end to age thresholds for prenatal genetic testing
8. Genetic testing of embryos
9. HPV testing could be future strategy for primary screening for cervical cancer
10. High-risk women welcome genetic testing for breast cancer gene
11. Biomedical scientist testing nanoparticles as early cancer detection agent

Post Your Comments:
(Date:5/24/2013)... Modulating the immune system to combat metastatic cancer ... and destruction by the immune system. Stimulation of the ... there are many factors that cause the immune system ... cells that function to suppress the immune system response. ... Investigation , researchers led by Ronald Levy at Stanford ...
(Date:5/24/2013)... non-coding RNAs are small molecules that help control ... they have emerged as disease biomarkers. miRNA profiles ... cancers of unknown primary origin, determine prognosis, monitor ... tractable, diagnostic methods for monitoring miRNA expression in ... issue of the Journal of Clinical Investigation ...
(Date:5/24/2013)... Alzheimer,s disease, scientists have focused among other factors ... all, it is the accumulation of A-beta that causes the ... for the formation of A-beta is APP. Alessia Soldano and ... function of APPL the fruit-fly version of APP ... Soldano (VIB/KU Leuven): "We have discovered that APPL ensures that ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... 2013 BioTrends Research Group, one of ... specialized biopharmaceutical issues, finds that, unaided, one in ... reported that in the past six months, they ... in anticipation of the next generation of HCV ... only 6 percent reported that they had begun ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013  Verenium ... biotechnology company focused on the development and commercialization of ... , Chief Financial Officer, will present at two ... Mr. Black will present at the Second Annual ... at the Grand Hyatt Hotel in New York City.  ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
Cached News: